A Phase III Study of Atezolizumab Immunotherapy and Chemotherapy Individually and Together for Untreated Advanced Bladder Cancer

Full Title

WO30070: A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as Monotherapy and in Combination with Platinum-Based Chemotherapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma


Atezolizumab is an immunotherapy drug used for previously treated bladder cancer as well as lung cancer. In this study, researchers are comparing atezolizumab and chemotherapy individually and together in patients with untreated advanced bladder cancer. Patients will be randomly assigned to receive atezolizumab alone, atezolizumab plus chemotherapy (gemcitabine and a platinum-containing drug), or chemotherapy and a placebo (inactive treatment).

Atezolizumab is designed to improve the immune system’s ability to recognize and destroy cancer cells by blocking PD-L1, a protein made by some cancers. Its use in this study is considered investigational. All of the medications used in this study are given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have inoperable or metastatic bladder cancer and may not have previously received chemotherapy.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Samuel Funt at 646-888-4770.